Overcoming Bottlenecks and Streamlining High-Throughput Screening for Drug Development

Biopharma companies typically maintain a library of over a million small-molecule drug candidates. The current industry standard of fluorescence-based assays for screening is resource-intensive, time-consuming, and leads to high failure rates during trials. At present, it takes about 10-15 years and nearly 1-2 billion dollars for a new drug candidate to receive approval for clinical use.

High-throughput screening using automated instruments is a necessary process to screen millions of samples efficiently and obtain high-quality data for informed and accurate decision-making earlier in the drug development pipeline. This will increase the chances of success of drug candidates in later stages of drug development, including clinical trials.

Integrated solutions like the SCIEX Echo MS+ are available to help companies accelerate high-throughput screening by streamlining every aspect of the process, from sample preparation to data reporting in mass spectrometry analysis. The typical sampling rate for the Echo MS+ is between 1 and 3 seconds, 30 to 90 times less per sample compared to traditional LC-MS. The higher volume of data generated doesn’t need to create a bottleneck on the back end as mass spectrometry data are automatically processed and reported by SCIEX OS software.

SCIEX Echo MS+ also allows label-free preparation of samples, ensuring data reliability, which leads to greater confidence in the analysis. It eliminates bottlenecks in screening and provides quality screening data quickly to allow companies to make faster decisions. By minimizing hands-on time for sample preparation and handling, the system delivers substantial time savings.

Automated solutions for high-throughput screening can protect valuable samples and help you get new drug candidates to the market faster. Contact an expert at the Life Sciences companies of Danaher to explore the range of available solutions.